{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:30:31Z","timestamp":1792009831139,"version":"4.4.0"},"reference-count":268,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Bone metastasis remains a significant cause of morbidity and diminished quality of life in patients with advanced breast, prostate, and lung cancers. Emerging research highlights the pivotal role of reversible epigenetic alterations, including DNA methylation, histone modifications, chromatin remodeling complex dysregulation, and non-coding RNA networks, in orchestrating each phase of skeletal colonization. Site-specific promoter hypermethylation of tumor suppressor genes such as HIN-1 and RASSF1A, alongside global DNA hypomethylation that activates metastasis-associated genes, contributes to cancer cell plasticity and facilitates epithelial-to-mesenchymal transition (EMT). Key histone modifiers, including KLF5, EZH2, and the demethylases KDM4\/6, regulate osteoclastogenic signaling pathways and the transition between metastatic dormancy and reactivation. Simultaneously, SWI\/SNF chromatin remodelers such as BRG1 and BRM reconfigure enhancer\u2013promoter interactions that promote bone tropism. Non-coding RNAs, including miRNAs, lncRNAs, and circRNAs (e.g., miR-34a, NORAD, circIKBKB), circulate via exosomes to modulate the RANKL\/OPG axis, thereby conditioning the bone microenvironment and fostering the formation of a pre-metastatic niche. These mechanistic insights have accelerated the development of epigenetic therapies. DNA methyltransferase inhibitors (e.g., decitabine, guadecitabine) have shown promise in attenuating osteoclast differentiation, while histone deacetylase inhibitors display context-dependent effects on tumor progression and bone remodeling. Inhibitors targeting EZH2, BET proteins, and KDM1A are now advancing through early-phase clinical trials, often in combination with bisphosphonates or immune checkpoint inhibitors. Moreover, novel approaches such as CRISPR\/dCas9-based epigenome editing and RNA-targeted therapies offer locus-specific reprogramming potential. Together, these advances position epigenetic modulation as a promising axis in precision oncology aimed at interrupting the pathological crosstalk between tumor cells and the bone microenvironment. This review synthesizes current mechanistic understanding, evaluates the therapeutic landscape, and outlines the translational challenges ahead in leveraging epigenetic science to prevent and treat bone metastases.<\/jats:p>","DOI":"10.3390\/ph18081140","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T06:37:47Z","timestamp":1754030267000},"page":"1140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-4984","authenticated-orcid":false,"given":"Mahmoud","family":"Zhra","sequence":"first","affiliation":[{"name":"Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-6740","authenticated-orcid":false,"given":"Jasmine Hanafy","family":"Holail","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9708-2111","authenticated-orcid":false,"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Arakil, N., Akhund, S.A., Elaasser, B., and Mohammad, K.S. (2024). Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051075"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3325\/cmj.2021.62.270","article-title":"The pathogenesis of bone metastasis in solid tumors: A review","volume":"62","author":"Belev","year":"2021","journal-title":"Croat. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Russo, S., Scotto di Carlo, F., and Gianfrancesco, F. (2022). The Osteoclast Traces the Route to Bone Tumors and Metastases. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.886305"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100597","DOI":"10.1016\/j.jbo.2024.100597","article-title":"The osteoblast in regulation of tumor cell dormancy and bone metastasis","volume":"45","author":"Zarrer","year":"2024","journal-title":"J. Bone Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"De Leon-Oliva, D., Barrena-Bl\u00e1zquez, S., Jim\u00e9nez-\u00c1lvarez, L., Fraile-Martinez, O., Garc\u00eda-Montero, C., L\u00f3pez-Gonz\u00e1lez, L., Torres-Carranza, D., Garc\u00eda-Puente, L.M., Carranza, S.T., and \u00c1lvarez-Mon, M. (2023). The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer. Medicina, 59.","DOI":"10.3390\/medicina59101752"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41413-020-00105-1","article-title":"Molecular mechanisms and clinical management of cancer bone metastasis","volume":"8","author":"Wang","year":"2020","journal-title":"Bone Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1002\/mco2.495","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/ijo.2022.5360","article-title":"Epigenetic modification regulates tumor progression and metastasis through EMT (Review)","volume":"60","author":"Tan","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Casalino, L., and Verde, P. (2020). Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Genes, 11.","DOI":"10.3390\/genes11080922"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Markouli, M., Strepkos, D., Basdra, E.K., Papavassiliou, A.G., and Piperi, C. (2021). Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052778"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/epi.12.50","article-title":"Chromatin Regulators with Tumor Suppressor Properties and their Alterations in Human Cancers","volume":"4","author":"Shu","year":"2012","journal-title":"Epigenomics"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Humphries, B., Wang, Z., and Yang, C. (2019). MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer. Cancers, 11.","DOI":"10.3390\/cancers11070897"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhang, S., Shen, T., and Zeng, Y. (2023). Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment. Cancers, 15.","DOI":"10.3390\/cancers15082243"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hu, D., Zhao, T., Xu, C., Pan, X., Zhou, Z., and Wang, S. (2024). Epigenetic Modifiers in Cancer Metastasis. Biomolecules, 14.","DOI":"10.3390\/biom14080916"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trsl.2014.04.001","article-title":"Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells","volume":"165","author":"Nickel","year":"2015","journal-title":"Transl. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2023.05.007","article-title":"Epigenetic regulation of epithelial-mesenchymal transition during cancer development","volume":"380","author":"Yoodee","year":"2023","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s00018-016-2303-1","article-title":"Epigenetic regulation of epithelial\u2013mesenchymal transition","volume":"73","author":"Sun","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dong, B., Qiu, Z., and Wu, Y. (2020). Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.596239"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-023-10109-y","article-title":"Epigenetic markers and therapeutic targets for metastasis","volume":"42","author":"Kravitz","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11914-023-00812-8","article-title":"Bone Trans-omics: Integrating Omics to Unveil Mechanistic Molecular Networks Regulating Bone Biology and Disease","volume":"21","author":"Mullin","year":"2023","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.csbj.2021.01.009","article-title":"Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis","volume":"19","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_22","first-page":"865","article-title":"Discovering DNA Methylation, the History and Future of the Writing on DNA","volume":"55","author":"Tompkins","year":"2022","journal-title":"J. Hist. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, S., Peng, Y., and Panchenko, A.R. (2022). DNA methylation: Precise modulation of chromatin structure and dynamics. Curr. Opin. Struct. Biol., 75.","DOI":"10.1016\/j.sbi.2022.102430"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shin, Y., Kim, S., and An, W. (2024). Promoter hypermethylation as a novel regulator of ANO1 expression and function in prostate cancer bone metastasis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62478-1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/15592294.2017.1311434","article-title":"DNA methylation aberrancies as a guide for surveillance and treatment of human cancers","volume":"12","author":"Liang","year":"2017","journal-title":"Epigenetics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41392-024-01938-6","article-title":"Circulating tumor cells: From new biological insights to clinical practice","volume":"9","author":"Gu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Besselink, N.J.M., Keijer, J.P., Vermeulen, C., Boymans, S., de Ridder, J., van Hoeck, A., Cuppen, E., and Kuijk, E.W. (2022). The genome-wide mutational consequences of DNA hypomethylation. Sci. Rep., 13.","DOI":"10.1101\/2022.10.04.510776"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-03-0118","article-title":"Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung","volume":"10","author":"Mehrotra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Feng, W., Orlandi, R., Zhao, N., Carcangiu, M.L., Tagliabue, E., Xu, J., Bast, R.C., and Yu, Y. (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-378"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2015.221","article-title":"Clinical utility of RASSF1A methylation in human malignancies","volume":"113","author":"Grawenda","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jos.2021.02.004","article-title":"The tumor suppressive role of TIMP3 in the human osteosarcoma cells","volume":"27","author":"Tan","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.4161\/epi.22333","article-title":"Heterogeneous epigenetic regulation of TIMP3 in prostate cancer","volume":"7","author":"Shinojima","year":"2012","journal-title":"Epigenetics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-019-2016-0","article-title":"Loss of TIMP3 by promoter methylation of Sp1 binding site promotes oral cancer metastasis","volume":"10","author":"Su","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2012.07.015","article-title":"Inhibition of Ca2+-activated Cl\u2212 channel ANO1\/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma","volume":"326","author":"Liu","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41419-018-0735-2","article-title":"Inhibition of ANO1\/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-\u03b1 signaling","volume":"9","author":"Song","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jia, L., Liu, W., Guan, L., Lu, M., and Wang, K. (2015). Inhibition of Calcium-Activated Chloride Channel ANO1\/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136584"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lai, Z., Shu, Q., Song, Y., Tang, A., and Tian, J. (2024). Effect of DNA methylation on the osteogenic differentiation of mesenchymal stem cells: Concise review. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1429844"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/jbmr.1491","article-title":"DNA methylation contributes to the regulation of sclerostin expression in human osteocytes","volume":"27","author":"Bolado","year":"2012","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12943-022-01697-4","article-title":"Targeting SOST using a small-molecule compound retards breast cancer bone metastasis","volume":"21","author":"Sun","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sun, M., Cao, Y., Yang, X., An, F., Wu, H., and Wang, J. (2021). DNA methylation in the OPG\/RANK\/RANKL pathway is associated with steroid-induced osteonecrosis of the femoral head. BMC Musculoskelet. Disord., 22.","DOI":"10.1186\/s12891-021-04472-6"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Li, B., Wang, P., Jiao, J., Wei, H., Xu, W., and Zhou, P. (2022). Roles of the RANKL\u2013RANK Axis in Immunity\u2014Implications for Pathogenesis and Treatment of Bone Metastasis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.824117"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Brouns, A., Hendriks, L.E.L., Robbesom-van den Berge, I.J., Driessen, A., Roemen, G., van Herpen, B.L.J., Dekkers, Z., Heitzer, B., Leunissen, D.J.G., and Moonen, L. (2023). Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1145001"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hayat, F., Khan, N.U., Khan, A.U., Ahmad, I., Alamri, A.M., and Iftikhar, B. (2022). Risk association of RANKL and OPG gene polymorphism with breast cancer to bone metastasis in Pashtun population of Khyber Pakhtunkhwa, Pakistan. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0276813"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1152\/physiol.00031.2024","article-title":"Role of RANKL Signaling in Bone Homeostasis","volume":"40","author":"Sobacchi","year":"2025","journal-title":"Physiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2015.352","article-title":"RANK\/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs","volume":"113","author":"Beuselinck","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/epi.7.1.18753","article-title":"Role of DNA methylation in the regulation of the RANKL-OPG system in human bone","volume":"7","author":"Fraga","year":"2012","journal-title":"Epigenetics"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Yalaev, B., Tyurin, A., Akhiiarova, K., and Khusainova, R. (2024). Hypomethylation of the RUNX2 Gene Is a New Potential Biomarker of Primary Osteoporosis in Men and Women. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137312"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canlet.2016.06.007","article-title":"RUNX2 promotes breast cancer bone metastasis by increasing integrin \u03b15-mediated colonization","volume":"380","author":"Li","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-15-0240","article-title":"ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGF\u03b2 Signaling Pathway","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/0008-5472.CAN-21-1331","article-title":"Extracellular Vesicle\u2013Packaged CDH11 and ITGA5 Induce the Premetastatic Niche for Bone Colonization of Breast Cancer Cells","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","article-title":"Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions","volume":"40","author":"Pantano","year":"2021","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.18632\/oncotarget.3192","article-title":"Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2473250","DOI":"10.1080\/15592294.2025.2473250","article-title":"TET-mediated 5hmC in breast cancer: Mechanism and clinical potential","volume":"20","author":"Zhang","year":"2025","journal-title":"Epigenetics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Xu, F., Li, W., Yang, X., Na, L., Chen, L., and Liu, G. (2021). The Roles of Epigenetics Regulation in Bone Metabolism and Osteoporosis. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.619301"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bellavia, D., Costa, V., De Luca, A., Cordaro, A., Fini, M., Giavaresi, G., Caradonna, F., and Raimondi, L. (2022). The Binomial \u201cInflammation-Epigenetics\u201d in Breast Cancer Progression and Bone Metastasis: IL-1\u03b2 Actions Are Influenced by TET Inhibitor in MCF-7 Cell Line. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315422"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Maroni, P., Matteucci, E., Bendinelli, P., and Desiderio, M.A. (2017). Functions and Epigenetic Regulation of Wwox in Bone Metastasis from Breast Carcinoma: Comparison with Primary Tumors. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010075"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhao, Z., and Shilatifard, A. (2019). Epigenetic modifications of histones in cancer. Genome Biol., 20.","DOI":"10.1186\/s13059-019-1870-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10409238.2019.1620676","article-title":"Preserving genome integrity and function: The DNA damage response and histone modifications","volume":"54","author":"Kim","year":"2019","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/14789450.2.5.719","article-title":"Histone structure and nucleosome stability","volume":"2","author":"Kann","year":"2005","journal-title":"Expert Rev. Proteom."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.sbi.2020.10.018","article-title":"Histone tails as signaling antennas of chromatin","volume":"67","author":"Peng","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/EBC20180061","article-title":"Acetylation & Co: An expanding repertoire of histone acylations regulates chromatin and transcription","volume":"63","author":"Barnes","year":"2019","journal-title":"Essays Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.7150\/ijms.43140","article-title":"The Role of Histone Acetyltransferases and Histone Deacetylases in Photoreceptor Differentiation and Degeneration","volume":"17","author":"Zhao","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hai, R., He, L., Shu, G., and Yin, G. (2021). Characterization of Histone Deacetylase Mechanisms in Cancer Development. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.700947"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semcancer.2021.03.001","article-title":"Targeting the acetylation signaling pathway in cancer therapy","volume":"85","author":"Dang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Trivedi, T., Pagnotti, G.M., Guise, T.A., and Mohammad, K.S. (2021). The Role of TGF-\u03b2 in Bone Metastases. Biomolecules, 11.","DOI":"10.3390\/biom11111643"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12307-011-0075-6","article-title":"TGF-\u03b2 in the Bone Microenvironment: Role in Breast Cancer Metastases","volume":"4","author":"Buijs","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41467-021-21976-w","article-title":"Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/MCB.00787-13","article-title":"KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells","volume":"33","author":"Zhang","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.7150\/thno.44567","article-title":"TGF-\u03b2 causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., and Dong, J.-T. (2023). Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. BMC Med., 21.","DOI":"10.1186\/s12916-023-02763-4"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_73","first-page":"2159","article-title":"Histone methyltransferases: Novel targets for tumor and developmental defects","volume":"7","author":"Yi","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.7150\/thno.104135","article-title":"JARID1D-dependent Androgen Receptor and JunD Signaling Activation of Osteoclast Differentiation Inhibits Prostate Cancer Bone Metastasis Through Demethylating H3K4","volume":"15","author":"Hu","year":"2025","journal-title":"Theranostics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/0008-5472.CAN-15-0906","article-title":"JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lemster, A.-L., Sievers, E., Pasternack, H., Lazar-Karsten, P., Kl\u00fcmper, N., Sailer, V., Offermann, A., Br\u00e4gelmann, J., Perner, S., and Kirfel, J. (2022). Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT. Cancers, 14.","DOI":"10.3390\/cancers14081894"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/0008-5472.CAN-20-0505","article-title":"KDM5B Is Essential for the Hyperactivation of PI3K\/AKT Signaling in Prostate Tumorigenesis","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41413-021-00145-1","article-title":"The KDM4B\u2013CCAR1\u2013MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis","volume":"9","author":"Yi","year":"2021","journal-title":"Bone Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.stem.2021.01.010","article-title":"Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging","volume":"28","author":"Deng","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.7150\/thno.58729","article-title":"Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer","volume":"11","author":"Wu","year":"2021","journal-title":"Theranostics"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wang, Z., Cai, H., Zhao, E., and Cui, H. (2022). The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.790129"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/abbs\/gmv107","article-title":"KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer","volume":"47","author":"Li","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biochi.2021.02.005","article-title":"KDM6B (JMJD3) and its dual role in cancer","volume":"184","year":"2021","journal-title":"Biochimie"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/2211-5463.13236","article-title":"Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt\/\u03b2-catenin signaling","volume":"11","author":"Xun","year":"2021","journal-title":"FEBS Open Bio"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Qin, M., Han, F., Wu, J., Gao, F.-x., Li, Y., Yan, D.-x., He, X.-m., Long, Y., Tang, X.-p., and Ren, D.-l. (2021). KDM6B promotes ESCC cell proliferation and metastasis by facilitating C\/EBP\u03b2 transcription. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08282-w"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.7150\/thno.53347","article-title":"KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1541-7786.MCR-14-0389","article-title":"Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer","volume":"13","author":"Salz","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/ijc.31853","article-title":"Aberrant expression of SETD1A promotes survival and migration of estrogen receptor \u03b1-positive breast cancer cells","volume":"143","author":"Jin","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Batham, J., Lim, P.S., and Rao, S. (2019). SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis. Cancers, 11.","DOI":"10.3390\/cancers11081143"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1158\/0008-5472.CAN-11-1052","article-title":"SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9","volume":"72","author":"Medjkane","year":"2012","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.molonc.2012.09.005","article-title":"Chromatin remodeling in cancer: A gateway to regulate gene transcription","volume":"6","author":"Nair","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1038\/s41388-021-01748-y","article-title":"ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer","volume":"40","author":"Moreno","year":"2021","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, X., Qiao, X., Xie, Y., Guo, D., Li, B., Cao, J., Tao, Z., and Hu, X. (2023). Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP. Cancers, 15.","DOI":"10.3390\/cancers15092447"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI123557","article-title":"Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/bph.14836","article-title":"Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance","volume":"178","author":"Puppo","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biochi.2021.05.003","article-title":"Regulation of bone metastasis and metastasis suppressors by non-coding RNAs in breast cancer","volume":"187","author":"Sanjeev","year":"2021","journal-title":"Biochimie"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/EBC20200032","article-title":"Non-coding RNA in cancer","volume":"65","author":"Yan","year":"2021","journal-title":"Essays Biochem."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Klinge, C.M. (2018). Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication. Non-Coding RNA, 4.","DOI":"10.3390\/ncrna4040040"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Maroni, P., Gomarasca, M., and Lombardi, G. (2023). Long non-coding RNAs in bone metastasis: Progresses and perspectives as potential diagnostic and prognostic biomarkers. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1156494"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Gilyazova, I., Gimalova, G., Nizamova, A., Galimova, E., Ishbulatova, E., Pavlov, V., and Khusnutdinova, E. (2024). Non-Coding RNAs as Key Regulators in Lung Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010560"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2174\/1568009620666200712144103","article-title":"Regulation of Breast Cancer Progression by Noncoding RNAs","volume":"20","author":"Akshaya","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Zhang, X., Wang, W., Zhu, W., Dong, J., Cheng, Y., Yin, Z., and Shen, F. (2019). Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225573"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.2174\/1381612825666190830161528","article-title":"Long Non-Coding RNAs As Epigenetic Regulators in Cancer","volume":"25","author":"Asma","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3892\/or.2016.4909","article-title":"The role of lncRNA MALAT1 in bone metastasis in patients with non-small cell lung cancer","volume":"36","author":"Liu","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/CAD.0000000000000650","article-title":"LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt\/mTOR signaling","volume":"29","author":"Tang","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref_106","first-page":"5143","article-title":"High Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Expression Promotes Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer via ERK\/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway","volume":"25","author":"Liu","year":"2019","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/s41467-024-46602-3","article-title":"Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13046-021-01891-0","article-title":"Long non-coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer","volume":"40","author":"Hu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4048\/jbc.2021.24.e32","article-title":"Long Non-Coding RNA NORAD Inhibits Breast Cancer Cell Proliferation and Metastasis by Regulating miR-155-5p\/SOCS1 Axis","volume":"24","author":"Liu","year":"2021","journal-title":"J. Breast Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2023.05.024","article-title":"MiRNA: What clinicians need to know","volume":"113","author":"Venneri","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"109995","DOI":"10.1016\/j.cellsig.2021.109995","article-title":"Micro-RNA: The darkhorse of cancer","volume":"83","author":"Budakoti","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11914-021-00677-9","article-title":"MicroRNAs and Their Roles in Breast Cancer Bone Metastasis","volume":"19","author":"Puppo","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kinget, L., Roussel, E., Lambrechts, D., Boeckx, B., Vanginderhuysen, L., Albersen, M., Rodr\u00edguez-Antona, C., Gra\u00f1a-Castro, O., Inglada-P\u00e9rez, L., and Verbiest, A. (2021). MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13071554"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/ijo.2021.5277","article-title":"Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis","volume":"59","author":"Kitayama","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Puppo, M., Jaafar, M., Diaz, J.-J., Marcel, V., and Cl\u00e9zardin, P. (2023). MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential. Cancers, 15.","DOI":"10.3390\/cancers15010242"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Gomarasca, M., Maroni, P., Banfi, G., and Lombardi, G. (2020). microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082805"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2018.03.035","article-title":"Circular RNAs (circRNAs) in cancer","volume":"425","author":"Zhou","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_118","first-page":"3463","article-title":"Circular RNAs: A novel target among non-coding RNAs with potential roles in malignant tumors (Review)","volume":"20","author":"Zhao","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e5503","DOI":"10.7717\/peerj.5503","article-title":"A comprehensive review of circRNA: From purification and identification to disease marker potential","volume":"6","author":"Xu","year":"2018","journal-title":"PeerJ"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-021-01394-8","article-title":"Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-\u03baB\/bone remodeling factors signaling","volume":"20","author":"Xu","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Jin, R., Sterling, J.A., Edwards, J.R., DeGraff, D.J., Lee, C., Park, S.I., and Matusik, R.J. (2013). Activation of NF-kappa B Signaling Promotes Growth of Prostate Cancer Cells in Bone. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060983"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/IJGM.S279023","article-title":"Clinical Significance of Has_circ_0060937 in Bone Metastasis of NSCLC","volume":"13","author":"Zhang","year":"2020","journal-title":"Int. J. Gen. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/0008-5472.CAN-23-1899","article-title":"CircMMP2(6,7) Cooperates with \u03b2-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Cao, P., and Zhu, Q. (2025). The regulatory role of m6A in cancer metastasis. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1539678"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/cac2.12458","article-title":"Roles and implications of mRNA N(6)-methyladenosine in cancer","volume":"43","author":"Zeng","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Dai, X.-Y., Shi, L., Li, Z., Yang, H.-Y., Wei, J.-F., and Ding, Q. (2021). Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.635329"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1002\/ctm2.426","article-title":"m6A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization","volume":"11","author":"Lang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"217047","DOI":"10.1016\/j.canlet.2024.217047","article-title":"YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation","volume":"597","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.7150\/ijms.108763","article-title":"Unraveling the Role of N6-Methylation Modification: From Bone Biology to Osteoporosis","volume":"22","author":"Liu","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1267\/ahc.24-00034","article-title":"CpG Methylation of Receptor Activator NF-\u03baB (RANK) Gene Promoter Region Delineates Senescence-Related Decrease of RANK Gene Expression","volume":"57","author":"Kitazawa","year":"2024","journal-title":"Acta Histochem. Cytochem."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"\u00d6lken, E.A., Aszodi, A., Taipaleenm\u00e4ki, H., Saito, H., Sch\u00f6nitzer, V., Chaloupka, M., Apfelbeck, M., B\u00f6cker, W., and Saller, M.M. (2022). SFRP2 Overexpression Induces an Osteoblast-like Phenotype in Prostate Cancer Cells. Cells, 11.","DOI":"10.3390\/cells11244081"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s42255-023-00948-y","article-title":"The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression","volume":"6","author":"Stegen","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41420-021-00472-6","article-title":"Histone modifications centric-regulation in osteogenic differentiation","volume":"7","author":"Li","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Montecino, M., Carrasco, M.E., and Nardocci, G. (2021). Epigenetic Control of Osteogenic Lineage Commitment. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.611197"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jbo.2016.04.002","article-title":"The role of microRNAs in bone metastasis","volume":"5","author":"Zoni","year":"2016","journal-title":"J. Bone Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Oka, S., Li, X., Zhang, F., Tewari, N., Ma, R., Zhong, L., Makishima, M., Liu, Y., and Bhawal, U.K. (2021). MicroRNA-21 facilitates osteoblast activity. Biochem. Biophys. Rep., 25.","DOI":"10.1016\/j.bbrep.2020.100894"},{"key":"ref_137","first-page":"1125","article-title":"miR-21 promotes osteoclastogenesis through activation of PI3K\/Akt signaling by targeting Pten in RAW264.7 cells","volume":"21","author":"Wang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/onc.2015.176","article-title":"A microRNA code for prostate cancer metastasis","volume":"35","author":"Bonci","year":"2016","journal-title":"Oncogene"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3892\/ijmm.2023.5287","article-title":"RAS-stimulated release of exosomal miR-494-3p promotes the osteolytic bone metastasis of breast cancer cells","volume":"52","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e12068","DOI":"10.1002\/jev2.12068","article-title":"Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche","volume":"10","author":"Ma","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"ref_141","first-page":"671","article-title":"Bone marrow stroma-derived miRNAs as regulators, biomarkers and therapeutic targets of bone metastasis","volume":"4","author":"Kang","year":"2015","journal-title":"BoneKEy Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e10183","DOI":"10.1002\/jbm4.10183","article-title":"Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease","volume":"3","author":"Adamik","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Raimondi, L., De Luca, A., Morelli, E., Giavaresi, G., Tagliaferri, P., Tassone, P., and Amodio, N. (2016). MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/6504593"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1359\/jbmr.2000.15.10.1912","article-title":"Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: Characteristic involvement of cell cycle regulators","volume":"15","author":"Tanaka","year":"2000","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.4028\/www.scientific.net\/KEM.361-363.1173","article-title":"Expression of ODF and ICAM-1 of Bone Marrow Mesenchymal Stem Cells is Enhanced with Osteogenic Differentiation","volume":"361\u2013363","author":"Wang","year":"2007","journal-title":"Key Eng. Mater."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15592294.2016.1271854","article-title":"Differential analysis of genome-wide methylation and gene expression in mesenchymal stem cells of patients with fractures and osteoarthritis","volume":"12","author":"Ibarbia","year":"2017","journal-title":"Epigenetics"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jbmr.3298","article-title":"Primary Osteoporosis Is Not Reflected by Disease-Specific DNA Methylation or Accelerated Epigenetic Age in Blood","volume":"33","author":"Eipel","year":"2018","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41413-023-00260-1","article-title":"Bone serves as a transfer station for secondary dissemination of breast cancer","volume":"11","author":"Huang","year":"2023","journal-title":"Bone Res."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Kim, K., Kim, I., Seong, S., Kook, H., Kim, K.K., Koh, J.-T., and Kim, N. (2021). Bifunctional Role of CrkL during Bone Remodeling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137007"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"405920","DOI":"10.1155\/2014\/405920","article-title":"Molecular regulation of bone marrow metastasis in prostate and breast cancer","volume":"2014","author":"Rahim","year":"2014","journal-title":"Bone Marrow Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1074\/jbc.M116.737379","article-title":"Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone","volume":"291","author":"Sharma","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1038\/ncomms7170","article-title":"NR2F1 controls tumour cell dormancy via SOX9- and RAR\u03b2-driven quiescence programmes","volume":"6","author":"Sosa","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e10125","DOI":"10.1002\/jbm4.10125","article-title":"Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities","volume":"3","author":"Byrne","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Singh, D.K., Patel, V.G., Oh, W.K., and Aguirre-Ghiso, J.A. (2021). Prostate Cancer Dormancy and Reactivation in Bone Marrow. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122648"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1541-7786.MCR-18-0956","article-title":"Identification of Genes Regulating Breast Cancer Dormancy in 3D Bone Endosteal Niche Cultures","volume":"17","author":"McGrath","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_156","first-page":"19","article-title":"The genetic architecture of bone metastases: Unveiling the role of epigenetic and genetic modifications in drug resistance","volume":"8","author":"Dawalibi","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1158\/0008-5472.CAN-05-1317","article-title":"Prostate Cancer Cells Promote Osteoblastic Bone Metastases through Wnts","volume":"65","author":"Hall","year":"2005","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/pros.22639","article-title":"Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases","volume":"73","author":"Larson","year":"2013","journal-title":"Prostate"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcdb.2022.11.002","article-title":"Epigenetic regulation of bone remodeling and bone metastasis","volume":"154","author":"Sharma","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"108640","DOI":"10.1016\/j.pharmthera.2024.108640","article-title":"Therapeutic targeting of DNA methylation alterations in cancer","volume":"258","author":"Lee","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.drudis.2021.05.015","article-title":"Unravelling KDM4 histone demethylase inhibitors for cancer therapy","volume":"26","author":"Baby","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.2174\/1568026619666181120150122","article-title":"DNA Methyltransferase Inhibitors and their Therapeutic Potential","volume":"18","author":"Zhou","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","article-title":"Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment","volume":"16","author":"Yu","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Wong, K.K., Hassan, R., and Yaacob, N.S. (2021). Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.624742"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Alexandraki, A., and Strati, K. (2022). Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214042"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0145-2126(84)90059-6","article-title":"Comparison of the antileukemic activity of 5-AZA-2\u2032-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia","volume":"8","author":"Momparler","year":"1984","journal-title":"Leuk. Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1593\/neo.07947","article-title":"Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo","volume":"10","author":"Ateeq","year":"2008","journal-title":"Neoplasia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cellsig.2015.02.006","article-title":"Decitabine represses osteoclastogenesis through inhibition of RANK and NF-\u03baB","volume":"27","author":"Guan","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","article-title":"DNMT1: A key drug target in triple-negative breast cancer","volume":"72","author":"Wong","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"100775","DOI":"10.1016\/j.tranon.2020.100775","article-title":"Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene","volume":"13","author":"Butler","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/13543784.2019.1667331","article-title":"Guadecitabine (SGI-110): An investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"28","author":"Merchan","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","volume":"2","author":"Pappalardi","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Wiseman, A.K., Tiedemann, R.L., Fan, H., Shen, H., Madaj, Z., McCabe, M.T., Pappalardi, M.B., and Jones, P.A. (2022). Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03509-3"},{"key":"ref_179","first-page":"816","article-title":"A safe and effective DNA hypomethylating agent","volume":"20","author":"Crunkhorn","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18632\/oncotarget.2695","article-title":"Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"ref_183","first-page":"293","article-title":"Current Treatment of Peripheral T-cell Lymphoma","volume":"36","author":"Stuver","year":"2022","journal-title":"Oncology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin. Epigenetics"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: A phase Ib trial","volume":"5","author":"Ho","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13318-021-00722-z","article-title":"Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing","volume":"46","author":"Liva","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cellsig.2016.11.002","article-title":"Class I histone deacetylases regulate p53\/NF-\u03baB crosstalk in cancer cells","volume":"29","author":"Beyer","year":"2017","journal-title":"Cell. Signal."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Kim, J.Y., Han, S.Y., Yoo, J., Kim, G.W., Jeon, Y.H., Lee, S.W., Park, J., and Kwon, S.H. (2022). HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158645"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e10694","DOI":"10.1002\/jbm4.10694","article-title":"Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy","volume":"7","author":"Clements","year":"2023","journal-title":"JBMR Plus"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11914-021-00670-2","article-title":"Targeting Histone Modifications in Bone and Lung Metastatic Cancers","volume":"19","author":"Edwards","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","article-title":"PRMTs and Arginine Methylation: Cancer\u2019s Best-Kept Secret?","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Taylor-Papadimitriou, J., and Burchell, J.M. (2022). Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer. Cells, 11.","DOI":"10.3390\/cells11071113"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 Inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-022-35059-x","article-title":"EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis","volume":"13","author":"Verma","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","article-title":"EZH2 engages TGF\u03b2 signaling to promote breast cancer bone metastasis via integrin \u03b21-FAK activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Varghese, B., Del Gaudio, N., Cobellis, G., Altucci, L., and Nebbioso, A. (2021). KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.750315"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"65548","DOI":"10.18632\/oncotarget.19214","article-title":"The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition","volume":"8","author":"Taube","year":"2017","journal-title":"Oncotarget"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jare.2024.04.009","article-title":"Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer","volume":"69","author":"Luo","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"Fso372","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: A review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"104499","DOI":"10.1016\/j.esmoop.2025.104499","article-title":"Final results from the phase Ia\/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma","volume":"10","author":"Lauer","year":"2025","journal-title":"ESMO Open"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"53997","DOI":"10.18632\/oncotarget.9804","article-title":"Targeting BET bromodomain proteins in solid tumors","volume":"7","author":"Sahai","year":"2016","journal-title":"Oncotarget"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"ref_206","first-page":"1335","article-title":"NUT midline carcinoma: An aggressive intrathoracic neoplasm","volume":"8","author":"Parikh","year":"2013","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","article-title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-023-36976-1","article-title":"BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas","volume":"14","author":"Moreno","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-023-00696-6","article-title":"Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis","volume":"18","author":"Harrison","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","article-title":"Epigenetic therapy inhibits metastases by disrupting premetastatic niches","volume":"579","author":"Lu","year":"2020","journal-title":"Nature"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Alexandrova, E., Smal, M., Di Rosa, D., Brancaccio, R.N., Parisi, R., Russo, F., Tarallo, R., Nassa, G., Giurato, G., and Weisz, A. (2025). BRPF1 inhibition reduces migration and invasion of metastatic ovarian cancer cells, representing a potential therapeutic target. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-92438-2"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Li, Z., Liu, P., Chen, W., Liu, X., Tong, F., Sun, J., Zhou, Y., Lei, T., Yang, W., and Ma, D. (2023). Hypoxia-cleavable and specific targeted nanomedicine delivers epigenetic drugs for enhanced treatment of breast cancer and bone metastasis. J. Nanobiotechnol., 21.","DOI":"10.1186\/s12951-023-01939-7"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12967-024-05554-4","article-title":"A systematic review of non-coding RNA therapeutics in early clinical trials: A new perspective against cancer","volume":"22","author":"Grillone","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Nappi, F. (2024). Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073630"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ncrna.2024.02.014","article-title":"MiRNAs as new potential biomarkers and therapeutic targets in brain metastasis","volume":"9","author":"Beylerli","year":"2024","journal-title":"Non-Coding RNA Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.18632\/oncotarget.3394","article-title":"Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"ref_219","first-page":"4493","article-title":"HSA-miR-34a-5p regulates the SIRT1\/TP53 axis in prostate cancer","volume":"14","author":"Wen","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Soghli, N., Ferns, G.A., Sadeghsoltani, F., Qujeq, D., Yousefi, T., and Vaghari-Tabari, M. (2022). MicroRNAs and osteosarcoma: Potential targets for inhibiting metastasis and increasing chemosensitivity. Biochem. Pharmacol., 201.","DOI":"10.1016\/j.bcp.2022.115094"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgz183","article-title":"miR-155 as a novel clinical target for hematological malignancies","volume":"41","author":"Witten","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Anfossi, S., Giordano, A., Gao, H., Cohen, E.N., Tin, S., Wu, Q., Garza, R.J., Debeb, B.G., Alvarez, R.H., and Valero, V. (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0083113"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/2013\/451248","article-title":"Regulation of breast cancer and bone metastasis by microRNAs","volume":"35","author":"Vimalraj","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.semcancer.2022.05.013","article-title":"Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches","volume":"86","author":"Shaath","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.csbj.2021.01.018","article-title":"Review on circular RNAs and new insights into their roles in cancer","volume":"19","author":"Tang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"He, W., Li, D., and Zhang, X. (2022). LncRNA HOTAIR promotes the proliferation and invasion\/metastasis of breast cancer cells by targeting the miR-130a-3p\/Suv39H1 axis. Biochem. Biophys. Rep., 30.","DOI":"10.1016\/j.bbrep.2022.101279"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2019.12.028","article-title":"HOTAIR LncRNA: A novel oncogenic propellant in human cancer","volume":"503","author":"Rajagopal","year":"2020","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41401-019-0234-8","article-title":"Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520b","volume":"40","author":"Zhang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1039\/D3AN01531A","article-title":"Long non-coding RNA (lncRNA) MALAT1 in regulating osteogenic and adipogenic differentiation using a double-stranded gapmer locked nucleic acid nanobiosensor","volume":"148","author":"Fasciano","year":"2023","journal-title":"Analyst"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41418-023-01160-x","article-title":"Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer","volume":"30","author":"Yang","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_233","first-page":"614","article-title":"The Emerging Role of Circular RNA Homeodomain Interacting Protein Kinase 3 and Circular RNA 0046367 through Wnt\/Beta-Catenin Pathway on the Pathogenesis of Nonalcoholic Steatohepatitis in Egyptian Patients","volume":"11","author":"Abdelgwad","year":"2023","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_234","first-page":"153","article-title":"Circular RNA 0001666 inhibits colorectal cancer cell proliferation, invasion and stemness by inactivating the Wnt\/\u03b2-catenin signaling pathway and targeting microRNA-1229","volume":"23","author":"Bai","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.omtn.2020.06.008","article-title":"Emerging Function and Clinical Significance of Exosomal circRNAs in Cancer","volume":"21","author":"Wang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"NPJ Vaccines"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Li, P., Lin, Z., Liu, Q., Chen, S., Gao, X., Guo, W., Gong, F., Wei, J., and Lin, H. (2021). Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK\/c-Fos Signaling Pathway. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.743840"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e2301310","DOI":"10.1002\/smtd.202301310","article-title":"An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy","volume":"8","author":"Gu","year":"2024","journal-title":"Small Methods"},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Qian, J., and Liu, S.X. (2024). CRISPR\/dCas9-Tet1-Mediated DNA Methylation Editing. Bio-Protocol, 14.","DOI":"10.21769\/BioProtoc.4976"},{"key":"ref_240","first-page":"170","article-title":"Long non-coding RNA in prostate cancer","volume":"10","author":"An","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.tranon.2023.101634","article-title":"Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review","volume":"31","author":"Ito","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Escuin, D., Bell, O., Garc\u00eda-Valdecasas, B., Clos, M., Larra\u00f1aga, I., L\u00f3pez-Vilar\u00f3, L., Mora, J., Andr\u00e9s, M., Arqueros, C., and Barnadas, A. (2024). Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073982"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/s41418-021-00762-7","article-title":"The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53","volume":"28","author":"Su","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1080\/21655979.2021.2020393","article-title":"High expression of small nucleolar RNA host gene 3 predicts poor prognosis and promotes bone metastasis in prostate cancer by activating transforming growth factor-beta signaling","volume":"13","author":"Xi","year":"2022","journal-title":"Bioengineered"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: Molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liang, J., Liu, P., Wang, Q., Liu, L., and Zhao, H. (2022). The RANK\/RANKL\/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1063815"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: Targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Kehrberg, R.J., Bhyravbhatla, N., Batra, S.K., and Kumar, S. (2023). Epigenetic regulation of cancer-associated fibroblast heterogeneity. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.188901"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1038\/ncomms4511","article-title":"Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle","volume":"5","author":"Lamoureux","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12935-024-03375-5","article-title":"Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution","volume":"24","author":"Mazzucchelli","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","article-title":"Mammalian SWI\/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","volume":"36","author":"Centore","year":"2020","journal-title":"Trends Genet."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-024-02015-w","article-title":"Assessment of SWI\/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer","volume":"23","author":"Zhuang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","article-title":"Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch\/Sucrose Non-Fermentable (SWI\/SNF) Dependent Cancers","volume":"68","author":"Vaswani","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ccell.2024.06.012","article-title":"Mammalian SWI\/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer","volume":"42","author":"Duplaquet","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bone.2016.09.020","article-title":"Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis","volume":"94","author":"Lamoureux","year":"2017","journal-title":"Bone"},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Khandekar, D., and Tiriveedhi, V. (2020). Role of BET Inhibitors in Triple Negative Breast Cancers. Cancers, 12.","DOI":"10.3390\/cancers12040784"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1038\/ncomms6418","article-title":"Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation","volume":"5","author":"Lim","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Huang, M., Qiu, Q., Xiao, Y., Zeng, S., Zhan, M., Shi, M., Zou, Y., Ye, Y., Liang, L., and Yang, X. (2016). BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS. Sci. Rep., 6.","DOI":"10.1038\/srep23770"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-21-0029","article-title":"Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"115492","DOI":"10.1016\/j.bone.2020.115492","article-title":"Targeting anti-cancer agents to bone using bisphosphonates","volume":"138","author":"Xing","year":"2020","journal-title":"Bone"},{"key":"ref_265","first-page":"e0400","article-title":"Castration resistant prostate cancer: Recent advances in novel therapeutic treatments","volume":"7","author":"Fatima","year":"2024","journal-title":"IJS Glob. Health"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"117185","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: A review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1078155218788706","article-title":"Incidence and management of adverse events associated with panobinostat in the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Moore","year":"2019","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:35Z","timestamp":1760033975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":268,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ph18081140"],"URL":"https:\/\/doi.org\/10.3390\/ph18081140","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}